Genetics in the Age of Precision Medicine
The completion of the Human Genome Project in 2003 promised a revolution in medicine. The revolution arrived, but more slowly and with more nuance than the early enthusiasm suggested. Your genome is not a destiny. It is a probability map. It tells you which biological pathways are more or less efficient in your particular physiology, which disease risks are elevated above the population average, and which drug and nutrient responses are likely based on your genetic makeup. Understanding how to use that information clinically is where precision medicine earns its name.
At Aeternitas Health, genomic information is one layer of a multi-modal precision health picture, not a standalone answer. Read with appropriate clinical interpretation, genomics supports a level of preventive personalization that standard medicine cannot offer. Read in isolation or without expert guidance, it produces anxiety without a clear course of action.
The Spectrum of Genetic Testing: Not All Tests Are Created Equal
Consumer genetics has made DNA information widely available. For longevity medicine, not all genetic testing carries the same clinical value. The differences are worth understanding before investing in any test.
Consumer Panels (23andMe, AncestryDNA)
Consumer genotyping panels test a selection of single nucleotide polymorphisms (SNPs), known variant sites in the genome. They are inexpensive, accessible, and well suited to ancestry analysis. For clinical longevity purposes, they provide limited but useful data on certain well-validated risk variants (such as APOE, and BRCA1/2 when included) and a narrow slice of disease risk. Their primary limitation is coverage: they test a small fraction of known clinically relevant variants, and their results are best confirmed with clinical-grade testing before they inform any medical decision.
Clinical Genetic Panels
Clinical panels test specific genes or gene sets associated with known hereditary disease risks: hereditary breast and ovarian cancer (BRCA1/2, PALB2, CHEK2), Lynch syndrome, and hereditary cardiovascular conditions (familial hypercholesterolemia, cardiomyopathy-associated genes), among others. These are ordered when personal or family history raises clinical suspicion, and they provide high-quality, clinically actionable data for the specific conditions they are designed to assess. This is the category Aeternitas uses, described in more detail below.
Whole Exome and Whole Genome Sequencing
Two broader research and clinical approaches sit beyond targeted panels. Whole exome sequencing (WES) reads the protein-coding regions of the roughly 20,000 human genes, the approximately 2 percent of the genome that encodes proteins and where the large majority of known disease-causing variants reside. Whole genome sequencing (WGS) reads the entire genome, coding and non-coding regions alike, and at sufficient depth can detect structural variants, deep intronic variants, and copy number variations that exome sequencing can miss. These methods provide broad coverage and are used in specialized precision medicine and rare-disease programs. They are not, despite the marketing around them, a finished or complete portrait: long-read sequencing is an emerging technology that detects some complex variants short-read sequencing cannot, and fully interpreted clinical-grade sequencing remains costly, commonly running well above a thousand dollars per person once analysis and interpretation are included.
Clinically Actionable Genomic Findings for Longevity
The useful question for a longevity-focused individual is not “what can my genome tell me?” but “what can I do differently based on what my genome tells me?” These are the categories where genomics most meaningfully changes clinical action.
APOE and Alzheimer’s Disease Risk
The APOE gene has three common variants: APOE2, APOE3, and APOE4. In people of European ancestry, carrying one copy of APOE4 is associated with roughly a three to four fold higher lifetime Alzheimer’s disease risk, and carrying two copies (APOE4/4) with a substantially higher risk, on the order of twelve to fifteen fold, relative to the common APOE3/3 genotype. These multiples are not fixed. They are lower in people of Black and Hispanic ancestry, higher in East Asian populations, and tend to be higher in women than men. APOE4 is neither necessary nor sufficient to cause Alzheimer’s disease; it shifts the odds, it does not set the outcome, and the figures come from observational studies.
Knowing APOE status before symptoms appear allows a prevention strategy calibrated to actual neurological risk. An APOE4 carrier may benefit from earlier and closer cardiovascular and neurological attention, careful management of ApoB and LDL, and earlier adoption of the sleep and exercise habits with the strongest neuroprotective evidence. Because an APOE4 result carries real emotional and counseling weight, we discuss whether and how a patient wants to receive it before testing, not after.
Familial Hypercholesterolemia Variants
Familial hypercholesterolemia (FH) affects roughly 1 in 250 people, the large majority of them undiagnosed. FH is caused by pathogenic variants in the LDLR, APOB, or PCSK9 genes that produce severely elevated LDL cholesterol from birth, accelerating atherosclerosis and raising lifetime cardiovascular event risk. Identifying FH supports early, sustained LDL-lowering therapy. The evidence for early treatment is strong, though largely observational: long-term follow-up suggests that people treated from a young age fare considerably better over the following decades than relatives who began treatment in adulthood. Identification also triggers cascade screening of first-degree relatives, who each carry a one-in-two chance of the same variant.
BRCA1/2 and Hereditary Cancer Risk
BRCA1 and BRCA2 pathogenic variants carry elevated lifetime cancer risks, with the specifics differing between the two genes. For BRCA1 carriers, cumulative breast cancer risk to age 80 is on the order of 72 percent and ovarian cancer risk on the order of 44 percent. BRCA2 carriers face a comparable breast cancer risk (roughly 55 to 69 percent) but a considerably lower ovarian cancer risk (roughly 13 to 29 percent), along with elevated risk of pancreatic and prostate cancer and melanoma. These are population estimates; an individual’s risk is modified by family history and other factors. Identification supports enhanced surveillance (MRI screening in addition to mammography, risk-reducing surgery where appropriate), risk-reduction strategies, and cascade genetic testing for family members who may be unaware of their own risk.
Pharmacogenomics: How Your Genes Affect Drug Response
Pharmacogenomics is one of the most actionable domains of clinical genetics, and several gene-drug pairs are now supported by formal prescribing guidance. Variants in the SLCO1B1 gene raise blood levels of certain statins and, with them, the risk of statin-associated muscle symptoms. Loss-of-function variants in CYP2C19 reduce the effectiveness of clopidogrel, a common antiplatelet medication used after coronary stenting, which is one of the most thoroughly validated pharmacogenomic findings in cardiology. Knowing a patient’s metabolizer status for these and other enzymes before a medication is prescribed can guide safer, more effective treatment selection. This is field-level context worth understanding; it is not a test Aeternitas runs in-house.
MTHFR and Methylation Pathways
MTHFR variants (C677T and A1298C) reduce the efficiency of folate metabolism and methylation, and the TT genotype in particular is associated with somewhat higher homocysteine. Consumer genetics has often treated these variants as more deterministic than the evidence supports, and the American College of Medical Genetics has cautioned against routine MTHFR testing. For a carrier with clinically elevated homocysteine, methylfolate (5-MTHF) is a biologically plausible alternative to folic acid because it bypasses the impaired enzymatic step. It is worth being clear about the limit of the evidence: no large trial has shown methylfolate to be superior to folic acid for hard outcomes, and folic acid remains the only folate form with proven efficacy in large trials for preventing neural tube defects.
What Genomics Cannot Tell You, and Why That Matters
Genetic literacy means understanding the limitations as clearly as the capabilities. Genomics cannot tell you:
- Whether you will develop any particular disease. It tells you only whether your risk is elevated relative to the general population.
- How much you can modify that risk through lifestyle, environment, and clinical intervention. That is where other precision medicine data (biomarkers, imaging, metabolic testing) provides essential context.
- How your epigenome, the layer of gene-expression regulation above the DNA sequence, is functioning. The epigenome responds more dynamically to environment and lifestyle than the fixed DNA sequence, and its marks are potentially reversible, which makes it a promising area of study. Routine clinical epigenomic testing for healthy people is not yet standard practice.
- Your pace of aging, for which longitudinal biomarker and functional testing provides more dynamic information than DNA sequence alone.
Genetics is not fate. An APOE4 carrier who maintains strong cardiovascular health, good sleep, regular physical activity, and tight metabolic control carries a lower Alzheimer’s risk than an APOE4 carrier who does not. Your genome establishes the terrain. Your choices, behaviors, and clinical management shape how you move across it.
Genomics at Aeternitas Health: Integrated, Not Isolated
At Aeternitas Health, genomic findings are read within the full precision longevity picture, not ordered in isolation and handed back as a report for you to interpret alone. Our genomic testing centers on a comprehensive hereditary-risk panel covering more than 160 genes, including the well-validated cancer-risk genes (BRCA1/2 and related hereditary cancer and endocrine genes), alongside APOE genotyping for those who choose it after we discuss what the result means. Where a personal or family history points to a question this testing does not answer, we coordinate the appropriate further evaluation.
What matters is what we do with the result. A genomic finding informs how we read biomarker panels, shapes imaging and cancer-screening priorities, and calibrates a personalized longevity plan to the biology of each individual member. We do not use genetics to produce fear. We use it to produce precision: the ability to focus prevention on the biological pathways where individual risk is highest and where early attention does the most to change a long-term trajectory.
If genomic testing as part of a comprehensive precision longevity program is something you are weighing, it is a conversation worth having with a physician who will read the result in context.
References
- Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology 2021;20(1):68-80. doi:10.1016/S1474-4422(20)30412-9.
- Belloy ME, Andrews SJ, Le Guen Y, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurology 2023;80(12):1284-1294. doi:10.1001/jamaneurol.2023.3599.
- Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. Journal of the American College of Cardiology 2018;72(6):662-680. doi:10.1016/j.jacc.2018.05.044.
- Besseling J, Hovingh GK, Huijgen R, Kastelein JJP, Hutten BA. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. Journal of the American College of Cardiology 2016;68(3):252-260. doi:10.1016/j.jacc.2016.04.054.
- Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112.
- National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (v3.2026).
- Piovesan A, Antonaros F, Vitale L, et al. Human protein-coding genes and gene feature statistics in 2019. BMC Research Notes 2019;12(1):315. doi:10.1186/s13104-019-4343-8.
- Wojcik MH, Lemire G, Berger E, et al. Genome sequencing for diagnosing rare diseases. The New England Journal of Medicine 2024;390(21):1985-1997. doi:10.1056/NEJMoa2314761.
- Pereira NL, Cresci S, Angiolillo DJ, et al. CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation 2024;150(6):e129-e150. doi:10.1161/CIR.0000000000001257.
- van den Broek WWA, Ingraham BS, Pereira NL, et al. Genotype-guided antiplatelet therapy: JACC review topic of the week. Journal of the American College of Cardiology 2024;84(12):1107-1118. doi:10.1016/j.jacc.2024.06.038.
- Fohr IP, Prinz-Langenohl R, Brönstrup A, et al. Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. The American Journal of Clinical Nutrition 2002;75(2):275-282. doi:10.1093/ajcn/75.2.275.
- Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. The New England Journal of Medicine 2018;378(14):1323-1334. doi:10.1056/NEJMra1402513.
Medically reviewed by Dr. Corey Helton, MD. Review date: June 2026
This article is for general educational purposes only. It is not medical advice and is not a substitute for diagnosis or treatment by a qualified physician. Reading it does not create a physician-patient relationship with Aeternitas. Talk with your own physician before making changes to your health, medications, supplements, or care.
